ReP USP - Resultado da busca

Artigo de periodico
Enhanced elimination of betamethasone in dichorionic twin pregnancies (2022)
Rodrigues, Grazielle de Fátima Pinto ; Benzi, Jhohann Richard de Lima ; Matos, Luísa Helena de Castro; Freitas, Stella Felippe de; Marques, Maria Paula ; Cavalli, Ricardo de Carvalho; Moisés, Elaine Christine Dantas ; Duarte, Geraldo; Lanchote, Vera Lucia ; Marcolin, Alessandra Cristina
Source: British Journal of Clinical Pharmacology. Unidades: FMRP, FCFRP
Subjects: GRAVIDEZ, FARMACOCINÉTICA, PLACENTA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RODRIGUES, Grazielle de Fátima Pinto et al. Enhanced elimination of betamethasone in dichorionic twin pregnancies. British Journal of Clinical Pharmacology, v. 88, n. 4, p. 1897-1903, 2022Tradução . . Disponível em: https://doi.org/10.1111/bcp.15111. Acesso em: 05 nov. 2024.
APA
Rodrigues, G. de F. P., Benzi, J. R. de L., Matos, L. H. de C., Freitas, S. F. de, Marques, M. P., Cavalli, R. de C., et al. (2022). Enhanced elimination of betamethasone in dichorionic twin pregnancies. British Journal of Clinical Pharmacology, 88( 4), 1897-1903. doi:10.1111/bcp.15111
NLM
Rodrigues G de FP, Benzi JR de L, Matos LH de C, Freitas SF de, Marques MP, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL, Marcolin AC. Enhanced elimination of betamethasone in dichorionic twin pregnancies [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 4): 1897-1903.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1111/bcp.15111
Vancouver
Rodrigues G de FP, Benzi JR de L, Matos LH de C, Freitas SF de, Marques MP, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL, Marcolin AC. Enhanced elimination of betamethasone in dichorionic twin pregnancies [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 4): 1897-1903.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1111/bcp.15111
Artigo de periodico
Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort (2022)
Ximenez, João Paulo Bianchi; Elias, Anna Beatriz Ribeiro; Nardotto, Glauco Henrique Balthazar ; Barroso, Paulo Feijó; Bollela, Valdes Roberto; Lanchote, Vera Lucia ; Suarez-Kurtz, Guilherme
Source: British Journal of Clinical Pharmacology. Unidades: FMRP, FCFRP
Subjects: FARMACOCINÉTICA, HIV, CITOCROMO P-450, GENÓTIPOS, INFECÇÕES POR HIV, FARMACOGENÉTICA, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
XIMENEZ, João Paulo Bianchi et al. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort. British Journal of Clinical Pharmacology, v. 88, n. 10, p. 4585-4594, 2022Tradução . . Disponível em: https://doi.org/10.1111/bcp.15387. Acesso em: 05 nov. 2024.
APA
Ximenez, J. P. B., Elias, A. B. R., Nardotto, G. H. B., Barroso, P. F., Bollela, V. R., Lanchote, V. L., & Suarez-Kurtz, G. (2022). Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort. British Journal of Clinical Pharmacology, 88( 10), 4585-4594. doi:10.1111/bcp.15387
NLM
Ximenez JPB, Elias ABR, Nardotto GHB, Barroso PF, Bollela VR, Lanchote VL, Suarez-Kurtz G. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 10): 4585-4594.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1111/bcp.15387
Vancouver
Ximenez JPB, Elias ABR, Nardotto GHB, Barroso PF, Bollela VR, Lanchote VL, Suarez-Kurtz G. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 10): 4585-4594.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1111/bcp.15387
Artigo de periodico
No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients (2022)
Nardotto, Glauco Henrique Balthazar ; Bollela, Valdes Roberto; Rocha, Adriana; Della Pasqua, Oscar; Lanchote, Vera Lucia
Source: Clinical and Translational Science. Unidades: FMRP, FCFRP
Subjects: HIV, FARMACOCINÉTICA, TUBERCULOSE, ESTUDOS PROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NARDOTTO, Glauco Henrique Balthazar et al. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients. Clinical and Translational Science, v. 15, p. 514-523, 2022Tradução . . Disponível em: https://doi.org/10.1111/cts.13169. Acesso em: 05 nov. 2024.
APA
Nardotto, G. H. B., Bollela, V. R., Rocha, A., Della Pasqua, O., & Lanchote, V. L. (2022). No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients. Clinical and Translational Science, 15, 514-523. doi:10.1111/cts.13169
NLM
Nardotto GHB, Bollela VR, Rocha A, Della Pasqua O, Lanchote VL. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients [Internet]. Clinical and Translational Science. 2022 ; 15 514-523.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1111/cts.13169
Vancouver
Nardotto GHB, Bollela VR, Rocha A, Della Pasqua O, Lanchote VL. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients [Internet]. Clinical and Translational Science. 2022 ; 15 514-523.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1111/cts.13169
Artigo de periodico
Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model (2021)
Pinto, Leonardo Santos Ribeiro; Bapat, Priya; Moreira, Fernanda de Lima; Lubetsky, Angelika; Cavalli, Ricardo de Carvalho; Berger, Howard; Lanchote, Vera Lucia ; Koren, Gideon
Source: Pharmaceutical Research. Unidades: FCFRP, FMRP
Subjects: ANTAGONISTAS, FARMACOTERAPIA, ANTIDEPRESSIVOS, PLACENTA, COMPLICAÇÕES NA GRAVIDEZ, ANTI-HISTAMÍNICOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model. Pharmaceutical Research, v. 38, n. 4, p. 647-655, 2021Tradução . . Disponível em: https://doi.org/10.1007/s11095-021-03035-7. Acesso em: 05 nov. 2024.
APA
Pinto, L. S. R., Bapat, P., Moreira, F. de L., Lubetsky, A., Cavalli, R. de C., Berger, H., et al. (2021). Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model. Pharmaceutical Research, 38( 4), 647-655. doi:10.1007/s11095-021-03035-7
NLM
Pinto LSR, Bapat P, Moreira F de L, Lubetsky A, Cavalli R de C, Berger H, Lanchote VL, Koren G. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model [Internet]. Pharmaceutical Research. 2021 ; 38( 4): 647-655.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1007/s11095-021-03035-7
Vancouver
Pinto LSR, Bapat P, Moreira F de L, Lubetsky A, Cavalli R de C, Berger H, Lanchote VL, Koren G. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model [Internet]. Pharmaceutical Research. 2021 ; 38( 4): 647-655.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1007/s11095-021-03035-7
Artigo de periodico
Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics (2021)
Pippa, Leandro Francisco ; Pereira, Maria Paula Marques ; Silva, Anna Christina Tojal da; Vilar, Fernando Crivelenti; Haes, Tissiana Marques de; Fonseca, Benedito Antonio Lopes da; Martinez, Roberto ; Coelho, Eduardo Barbosa ; Wichert-Ana, Lauro; Lanchote, Vera Lucia
Source: Frontiers in Chemistry. Unidades: FCFRP, FMRP, EERP
Subjects: ANTIFÚNGICOS, LÍQUIDO CEFALORRAQUIDIANO, FARMACOCINÉTICA, PLASMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIPPA, Leandro Francisco et al. Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics. Frontiers in Chemistry, v. 9, p. 1-14, 2021Tradução . . Disponível em: https://doi.org/10.3389/fchem.2021.782131. Acesso em: 05 nov. 2024.
APA
Pippa, L. F., Pereira, M. P. M., Silva, A. C. T. da, Vilar, F. C., Haes, T. M. de, Fonseca, B. A. L. da, et al. (2021). Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics. Frontiers in Chemistry, 9, 1-14. doi:10.3389/fchem.2021.782131
NLM
Pippa LF, Pereira MPM, Silva ACT da, Vilar FC, Haes TM de, Fonseca BAL da, Martinez R, Coelho EB, Wichert-Ana L, Lanchote VL. Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics [Internet]. Frontiers in Chemistry. 2021 ; 9 1-14.[citado 2024 nov. 05 ] Available from: https://doi.org/10.3389/fchem.2021.782131
Vancouver
Pippa LF, Pereira MPM, Silva ACT da, Vilar FC, Haes TM de, Fonseca BAL da, Martinez R, Coelho EB, Wichert-Ana L, Lanchote VL. Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics [Internet]. Frontiers in Chemistry. 2021 ; 9 1-14.[citado 2024 nov. 05 ] Available from: https://doi.org/10.3389/fchem.2021.782131
Artigo de periodico
PK/PD approach to evaluate Meropenem effectiveness in critically ill burn adolescents versus young adults undergoing therapy of septic shock (2021)
Camargo, Thais Vieira de; Silva Júnior, João Manoel da; Silva Junior, Elson Mendes da; Santos, Verônica Jorge; Rocha, Adriana; Lanchote, Vera Lucia ; Santos, Silvia Regina Cavani Jorge ; Gomez, David de Souza
Source: Brazilian Journal of Health Review. Unidades: FM, FCFRP, FCF
Subjects: FARMACOCINÉTICA, FARMACODINÂMICA, CHOQUE SÉPTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAMARGO, Thais Vieira de et al. PK/PD approach to evaluate Meropenem effectiveness in critically ill burn adolescents versus young adults undergoing therapy of septic shock. Brazilian Journal of Health Review, v. 4, n. 1, p. 1213-1232, 2021Tradução . . Disponível em: https://doi.org/10.34119/bjhrv4n1-107. Acesso em: 05 nov. 2024.
APA
Camargo, T. V. de, Silva Júnior, J. M. da, Silva Junior, E. M. da, Santos, V. J., Rocha, A., Lanchote, V. L., et al. (2021). PK/PD approach to evaluate Meropenem effectiveness in critically ill burn adolescents versus young adults undergoing therapy of septic shock. Brazilian Journal of Health Review, 4( 1), 1213-1232. doi:10.34119/bjhrv4n1-107
NLM
Camargo TV de, Silva Júnior JM da, Silva Junior EM da, Santos VJ, Rocha A, Lanchote VL, Santos SRCJ, Gomez D de S. PK/PD approach to evaluate Meropenem effectiveness in critically ill burn adolescents versus young adults undergoing therapy of septic shock [Internet]. Brazilian Journal of Health Review. 2021 ; 4( 1): 1213-1232.[citado 2024 nov. 05 ] Available from: https://doi.org/10.34119/bjhrv4n1-107
Vancouver
Camargo TV de, Silva Júnior JM da, Silva Junior EM da, Santos VJ, Rocha A, Lanchote VL, Santos SRCJ, Gomez D de S. PK/PD approach to evaluate Meropenem effectiveness in critically ill burn adolescents versus young adults undergoing therapy of septic shock [Internet]. Brazilian Journal of Health Review. 2021 ; 4( 1): 1213-1232.[citado 2024 nov. 05 ] Available from: https://doi.org/10.34119/bjhrv4n1-107
Artigo de periodico
Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A (2021)
Tozatto, Eduardo; Benzi, Jhohann Richard de Lima ; Rocha, Adriana; Coelho, Eduardo Barbosa ; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: FÁRMACOS, HIPERTENSÃO, FARMACOCINÉTICA, ANTIDEPRESSIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TOZATTO, Eduardo et al. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, v. 61, n. 3, p. 319-327, 2021Tradução . . Disponível em: https://doi.org/10.1002/jcph.1745. Acesso em: 05 nov. 2024.
APA
Tozatto, E., Benzi, J. R. de L., Rocha, A., Coelho, E. B., & Lanchote, V. L. (2021). Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, 61( 3), 319-327. doi:10.1002/jcph.1745
NLM
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1002/jcph.1745
Vancouver
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1002/jcph.1745
Artigo de periodico-carta/editorial
Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] (2020)
Gonçalves, Paulo Vinícius Bernardes; Moreira, Fernanda de Lima; Benzi, Jhohann Richard de Lima ; Cavalli, Ricardo de Carvalho; Duarte, Geraldo; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: FARMACOCINÉTICA, TRABALHO DE PARTO INDUZIDO, HIPERTENSÃO NA GRAVIDEZ
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GONÇALVES, Paulo Vinícius Bernardes et al. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1002/jcph.1719. Acesso em: 05 nov. 2024. , 2020
APA
Gonçalves, P. V. B., Moreira, F. de L., Benzi, J. R. de L., Cavalli, R. de C., Duarte, G., & Lanchote, V. L. (2020). Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.1002/jcph.1719
NLM
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1002/jcph.1719
Vancouver
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1002/jcph.1719
Artigo de periodico
Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study (2020)
Pinto, Leonardo Santos Ribeiro; Vale, Gabriel Tavares do ; Moreira, Fernanda de Lima ; Pereira, Maria Paula Marques ; Coelho, Eduardo Barbosa ; Cavalli, Ricardo de Carvalho ; Lanchote, Vera Lucia
Source: Journal of Chromatography B. Unidades: FCFRP, FMRP, EERP
Subjects: ANTI-HISTAMÍNICOS, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, PLASMA, GRAVIDEZ, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. Journal of Chromatography B, v. 1145, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jchromb.2020.122094. Acesso em: 05 nov. 2024.
APA
Pinto, L. S. R., Vale, G. T. do, Moreira, F. de L., Pereira, M. P. M., Coelho, E. B., Cavalli, R. de C., & Lanchote, V. L. (2020). Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. Journal of Chromatography B, 1145. doi:10.1016/j.jchromb.2020.122094
NLM
Pinto LSR, Vale GT do, Moreira F de L, Pereira MPM, Coelho EB, Cavalli R de C, Lanchote VL. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Chromatography B. 2020 ; 1145[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122094
Vancouver
Pinto LSR, Vale GT do, Moreira F de L, Pereira MPM, Coelho EB, Cavalli R de C, Lanchote VL. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Chromatography B. 2020 ; 1145[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122094
Artigo de periodico
Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio (2020)
Pippa, Leandro Francisco ; Oliveira, Milena Locci de ; Rocha, Adriana; Andrade, Jurandyr Moreira de ; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: ANTINEOPLÁSICOS, FARMACOCINÉTICA, VARIAÇÃO (BIOLOGIA), NEOPLASIAS MAMÁRIAS, MIOCARDIOPATIA CONGESTIVA, QUIMIOTERAPIA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIPPA, Leandro Francisco et al. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis, v. 185, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113231. Acesso em: 05 nov. 2024.
APA
Pippa, L. F., Oliveira, M. L. de, Rocha, A., Andrade, J. M. de, & Lanchote, V. L. (2020). Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis, 185. doi:10.1016/j.jpba.2020.113231
NLM
Pippa LF, Oliveira ML de, Rocha A, Andrade JM de, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.jpba.2020.113231
Vancouver
Pippa LF, Oliveira ML de, Rocha A, Andrade JM de, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.jpba.2020.113231
Artigo de periodico
Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease (2020)
Schaab, Estela Hanauer; Lanchote, Vera Lucia ; Nardotto, Glauco Henrique Balthazar ; Pereira, Maria Paula Marques ; Dantas, Márcio ; Paiva, Carlos Eduardo; Coelho, Eduardo Barbosa
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: NEFROPATIAS, INTERAÇÃO ENTRE ALIMENTOS E MEDICAMENTOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCHAAB, Estela Hanauer et al. Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease. The Journal of Clinical Pharmacology, v. 60, n. 1, p. 75-85, 2020Tradução . . Disponível em: https://doi.org/10.1002/jcph.1485. Acesso em: 05 nov. 2024.
APA
Schaab, E. H., Lanchote, V. L., Nardotto, G. H. B., Pereira, M. P. M., Dantas, M., Paiva, C. E., & Coelho, E. B. (2020). Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease. The Journal of Clinical Pharmacology, 60( 1), 75-85. doi:10.1002/jcph.1485
NLM
Schaab EH, Lanchote VL, Nardotto GHB, Pereira MPM, Dantas M, Paiva CE, Coelho EB. Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 1): 75-85.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1002/jcph.1485
Vancouver
Schaab EH, Lanchote VL, Nardotto GHB, Pereira MPM, Dantas M, Paiva CE, Coelho EB. Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 1): 75-85.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1002/jcph.1485
Artigo de periodico
Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia (2020)
Oliveira, Milena Locci de ; Rocha, Adriana; Nardotto, Glauco Henrique Balthazar ; Pippa, Leandro Francisco ; Simões, Belinda Pinto ; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: LEUCEMIA MIELOIDE AGUDA, ANTINEOPLÁSICOS, METABÓLITOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Milena Locci de et al. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis, v. 191, p. 1-8, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113576. Acesso em: 05 nov. 2024.
APA
Oliveira, M. L. de, Rocha, A., Nardotto, G. H. B., Pippa, L. F., Simões, B. P., & Lanchote, V. L. (2020). Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis, 191, 1-8. doi:10.1016/j.jpba.2020.113576
NLM
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 191 1-8.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.jpba.2020.113576
Vancouver
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 191 1-8.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.jpba.2020.113576
Artigo de periodico
Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers (2020)
Cestari, Roberta Natália ; Caris, Juciene Aparecida ; Rocha, Adriana; Nardotto, Glauco Henrique Balthazar ; Oliveira, Renê Donizeti Ribeiro de; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: ESTATINAS, FARMACOCINÉTICA, FARMACOLOGIA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, COMPOSTOS ORGÂNICOS, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CESTARI, Roberta Natália et al. Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. Journal of Pharmaceutical and Biomedical Analysis, v. 182, p. 1-7, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113128. Acesso em: 05 nov. 2024.
APA
Cestari, R. N., Caris, J. A., Rocha, A., Nardotto, G. H. B., Oliveira, R. D. R. de, & Lanchote, V. L. (2020). Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. Journal of Pharmaceutical and Biomedical Analysis, 182, 1-7. doi:10.1016/j.jpba.2020.113128
NLM
Cestari RN, Caris JA, Rocha A, Nardotto GHB, Oliveira RDR de, Lanchote VL. Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 182 1-7.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.jpba.2020.113128
Vancouver
Cestari RN, Caris JA, Rocha A, Nardotto GHB, Oliveira RDR de, Lanchote VL. Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 182 1-7.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.jpba.2020.113128
Trabalho de evento-resumo periodico
Pegylating toxins: anew trend in toxinology? A successful example of a PEGylated snake venom serine protease (2020)
Pinheiro-Júnior, Ernesto Lopes ; Boldrini-França, Johara; Costa, Tássia Rafaella; Takeda, Agnes Alessandra; Sampaio, Suely Vilela ; Fontes, Marcos Roberto de Mattos ; Peigneur, Steve; Tytgat, Jan; Arantes, Eliane Candiani
Source: Toxicon. Conference titles: World Congress of the International-Society-on-Toxinology. Unidade: FCFRP
Subjects: TOXICOLOGIA, TOXINAS, COBRAS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINHEIRO-JÚNIOR, Ernesto Lopes et al. Pegylating toxins: anew trend in toxinology? A successful example of a PEGylated snake venom serine protease. Toxicon. Oxford: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.toxicon.2019.12.134. Acesso em: 05 nov. 2024. , 2020
APA
Pinheiro-Júnior, E. L., Boldrini-França, J., Costa, T. R., Takeda, A. A., Sampaio, S. V., Fontes, M. R. de M., et al. (2020). Pegylating toxins: anew trend in toxinology? A successful example of a PEGylated snake venom serine protease. Toxicon. Oxford: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.toxicon.2019.12.134
NLM
Pinheiro-Júnior EL, Boldrini-França J, Costa TR, Takeda AA, Sampaio SV, Fontes MR de M, Peigneur S, Tytgat J, Arantes EC. Pegylating toxins: anew trend in toxinology? A successful example of a PEGylated snake venom serine protease [Internet]. Toxicon. 2020 ; 177 S58-S59.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.toxicon.2019.12.134
Vancouver
Pinheiro-Júnior EL, Boldrini-França J, Costa TR, Takeda AA, Sampaio SV, Fontes MR de M, Peigneur S, Tytgat J, Arantes EC. Pegylating toxins: anew trend in toxinology? A successful example of a PEGylated snake venom serine protease [Internet]. Toxicon. 2020 ; 177 S58-S59.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.toxicon.2019.12.134
Artigo de periodico-carta/editorial
Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta] (2020)
Vieira, Carolina Pinto; Neves, Daniel Valente; Nardotto, Glauco Henrique Balthazar; Cesarino, Evandro José ; Rocha, Adriana; Zanardi, Ailton Marcelo Castilho Teno; Lanchote, Vera Lucia
Source: European Journal of Clinical Pharmacology. Unidade: FCFRP
Subjects: BETA-BLOQUEADORES, HIPERTENSÃO, METABOLISMO, IDOSOS, FARMACOCINÉTICA, DOENÇA DE CHAGAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIEIRA, Carolina Pinto et al. Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta]. European Journal of Clinical Pharmacology. Heidelberg: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1007/s00228-020-02837-9. Acesso em: 05 nov. 2024. , 2020
APA
Vieira, C. P., Neves, D. V., Nardotto, G. H. B., Cesarino, E. J., Rocha, A., Zanardi, A. M. C. T., & Lanchote, V. L. (2020). Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta]. European Journal of Clinical Pharmacology. Heidelberg: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.1007/s00228-020-02837-9
NLM
Vieira CP, Neves DV, Nardotto GHB, Cesarino EJ, Rocha A, Zanardi AMCT, Lanchote VL. Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta] [Internet]. European Journal of Clinical Pharmacology. 2020 ; 76( 5): 735-737.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1007/s00228-020-02837-9
Vancouver
Vieira CP, Neves DV, Nardotto GHB, Cesarino EJ, Rocha A, Zanardi AMCT, Lanchote VL. Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. [Carta] [Internet]. European Journal of Clinical Pharmacology. 2020 ; 76( 5): 735-737.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1007/s00228-020-02837-9
Artigo de periodico
Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics (2020)
Pinto, Leonardo Santos Ribeiro; Moreira, Fernanda de Lima ; Nardotto, Glauco Henrique Balthazar ; Cavalli, Ricardo de Carvalho ; Moisés, Elaine Christine Dantas ; Duarte, Geraldo ; Lanchote, Vera Lucia
Source: Pharmaceutical Research. Unidades: FCFRP, FMRP
Subjects: ANTIDEPRESSIVOS, FARMACOCINÉTICA, GRAVIDEZ, ESTUDOS DE CASOS E CONTROLES, MUCOSA INTESTINAL, ANTI-HISTAMÍNICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics. Pharmaceutical Research, v. 37, n. 7, 2020Tradução . . Disponível em: https://doi.org/10.1007/s11095-020-02854-4. Acesso em: 05 nov. 2024.
APA
Pinto, L. S. R., Moreira, F. de L., Nardotto, G. H. B., Cavalli, R. de C., Moisés, E. C. D., Duarte, G., & Lanchote, V. L. (2020). Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics. Pharmaceutical Research, 37( 7). doi:10.1007/s11095-020-02854-4
NLM
Pinto LSR, Moreira F de L, Nardotto GHB, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL. Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics [Internet]. Pharmaceutical Research. 2020 ; 37( 7):[citado 2024 nov. 05 ] Available from: https://doi.org/10.1007/s11095-020-02854-4
Vancouver
Pinto LSR, Moreira F de L, Nardotto GHB, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL. Chiral discrimination of p-glycoprotein in parturient women: effect of fluoxetine on maternal-fetal fexofenadine pharmacokinetics [Internet]. Pharmaceutical Research. 2020 ; 37( 7):[citado 2024 nov. 05 ] Available from: https://doi.org/10.1007/s11095-020-02854-4
Artigo de periodico
Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin (2020)
Cestari, Roberta Natália ; Oliveira, Renê Donizeti Ribeiro de; Souza, Flávio Falcão Lima de; Pippa, Leandro Francisco ; Nardotto, Glauco Henrique Balthazar ; Rocha, Adriana; Donadi, Eduardo Antônio ; Lanchote, Vera Lucia
Source: Clinical and Translational Science. Unidades: FMRP, FCFRP
Subjects: LÚPUS ERITEMATOSO SISTÊMICO, FARMACOCINÉTICA, FÁRMACOS, ESTATINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CESTARI, Roberta Natália et al. Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin. Clinical and Translational Science, v. 13, n. 6, p. 1227-1235, 2020Tradução . . Disponível em: https://doi.org/10.1111/cts.12808. Acesso em: 05 nov. 2024.
APA
Cestari, R. N., Oliveira, R. D. R. de, Souza, F. F. L. de, Pippa, L. F., Nardotto, G. H. B., Rocha, A., et al. (2020). Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin. Clinical and Translational Science, 13( 6), 1227-1235. doi:10.1111/cts.12808
NLM
Cestari RN, Oliveira RDR de, Souza FFL de, Pippa LF, Nardotto GHB, Rocha A, Donadi EA, Lanchote VL. Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin [Internet]. Clinical and Translational Science. 2020 ; 13( 6): 1227-1235.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1111/cts.12808
Vancouver
Cestari RN, Oliveira RDR de, Souza FFL de, Pippa LF, Nardotto GHB, Rocha A, Donadi EA, Lanchote VL. Systemic Lupus Erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of Atorvastatin [Internet]. Clinical and Translational Science. 2020 ; 13( 6): 1227-1235.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1111/cts.12808
Artigo de periodico
Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics (2020)
Godoy, Ana Leonor Pardo Campos; Jesus, Clauceane de; Gonçalves, Rafaela S.; Azeredo, Francine Johansson; Rocha, Adriana; Marques, Maria Paula ; Lanchote, Vera Lucia ; Larangeira, Daniela Farias; Barrouin-Melo, Stella Maria
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidade: FCFRP
Subjects: ÁCIDO ÚRICO, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, CÃES, URINA, PARASITOLOGIA, LEISHMANIA INFANTUM, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GODOY, Ana Leonor Pardo Campos et al. Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, v. 185, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113204. Acesso em: 05 nov. 2024.
APA
Godoy, A. L. P. C., Jesus, C. de, Gonçalves, R. S., Azeredo, F. J., Rocha, A., Marques, M. P., et al. (2020). Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 185. doi:10.1016/j.jpba.2020.113204
NLM
Godoy ALPC, Jesus C de, Gonçalves RS, Azeredo FJ, Rocha A, Marques MP, Lanchote VL, Larangeira DF, Barrouin-Melo SM. Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.jpba.2020.113204
Vancouver
Godoy ALPC, Jesus C de, Gonçalves RS, Azeredo FJ, Rocha A, Marques MP, Lanchote VL, Larangeira DF, Barrouin-Melo SM. Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.jpba.2020.113204
Artigo de periodico
Pharmacokinetics and placental transfer of bupivacaine enantiomers in HIV-infected parturient women on antiretroviral therapy (2020)
Souza, Marília Cristina Oliveira ; Pereira, Maria Paula Marques ; Duarte, Geraldo ; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: ANESTÉSICOS, PARTO, FARMACOCINÉTICA, HIV
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, Marília Cristina Oliveira et al. Pharmacokinetics and placental transfer of bupivacaine enantiomers in HIV-infected parturient women on antiretroviral therapy. The Journal of Clinical Pharmacology, v. 60, n. 5, p. 566-572, 2020Tradução . . Disponível em: https://doi.org/10.1002/jcph.1554. Acesso em: 05 nov. 2024.
APA
Souza, M. C. O., Pereira, M. P. M., Duarte, G., & Lanchote, V. L. (2020). Pharmacokinetics and placental transfer of bupivacaine enantiomers in HIV-infected parturient women on antiretroviral therapy. The Journal of Clinical Pharmacology, 60( 5), 566-572. doi:10.1002/jcph.1554
NLM
Souza MCO, Pereira MPM, Duarte G, Lanchote VL. Pharmacokinetics and placental transfer of bupivacaine enantiomers in HIV-infected parturient women on antiretroviral therapy [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 5): 566-572.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1002/jcph.1554
Vancouver
Souza MCO, Pereira MPM, Duarte G, Lanchote VL. Pharmacokinetics and placental transfer of bupivacaine enantiomers in HIV-infected parturient women on antiretroviral therapy [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 5): 566-572.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1002/jcph.1554
Artigo de periodico
Changes in tramadol enantioselective pharmacokinetics and metabolism in rats with experimental diabetes treated or not with insulin (2019)
Godoy, Ana Leonor Pardo Campos; Moraes, Natália Valadares de; Benzi, Jhohann Richard de Lima ; Lanchote, Vera Lucia
Source: European Journal of Pharmaceutical Sciences. Unidade: FCFRP
Subjects: DIABETES MELLITUS, ANALGÉSICOS, GLICOSE, INSULINA, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GODOY, Ana Leonor Pardo Campos et al. Changes in tramadol enantioselective pharmacokinetics and metabolism in rats with experimental diabetes treated or not with insulin. European Journal of Pharmaceutical Sciences, v. 128, p. 97-102, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.ejps.2018.11.032. Acesso em: 05 nov. 2024.
APA
Godoy, A. L. P. C., Moraes, N. V. de, Benzi, J. R. de L., & Lanchote, V. L. (2019). Changes in tramadol enantioselective pharmacokinetics and metabolism in rats with experimental diabetes treated or not with insulin. European Journal of Pharmaceutical Sciences, 128, 97-102. doi:10.1016/j.ejps.2018.11.032
NLM
Godoy ALPC, Moraes NV de, Benzi JR de L, Lanchote VL. Changes in tramadol enantioselective pharmacokinetics and metabolism in rats with experimental diabetes treated or not with insulin [Internet]. European Journal of Pharmaceutical Sciences. 2019 ; 128 97-102.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.ejps.2018.11.032
Vancouver
Godoy ALPC, Moraes NV de, Benzi JR de L, Lanchote VL. Changes in tramadol enantioselective pharmacokinetics and metabolism in rats with experimental diabetes treated or not with insulin [Internet]. European Journal of Pharmaceutical Sciences. 2019 ; 128 97-102.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.ejps.2018.11.032

USP Schools

ReP

Filtros

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Publisher

Conference titles

Countries/Territories

Funding Agencies

Indexado em

Non normalized affiliation

Countries of institutions of collaboration